Mr Elias Zerhouni, Sanofi global R&D president (Photo Courtesy: www.article.wn.com)
The agreement is expected to be effective as of March 31.
This strategic collaboration aims to sustain a high level of scientific and technological activities, maintain jobs and attract new talent and projects to the site.
"I commend and thank our on-site team members for their hard work and commitment to this project, which is a major opportunity for the Toulouse site. I would also like to express my appreciation to all the stakeholders - elected officials, authorities, associations, members of the scientific community - whose invaluable support has made this project possible," said Mr Elias Zerhouni, Sanofi global R&D president.
In particular, the agreement includes the divestiture to Evotec of the site's Research and Technological platform activities which match Evotec's areas of expertise as well as the continuation of these activities and the corresponding transfer of the employees currently involved in these activities.
For Sanofi, the strategic collaboration also involves a financial commitment of € 250 million over a five-year period for the implementation of a multi-year research program including, among other projects, the creation of a support fund dedicated to developing scientific collaboration with academic partners in France.
